Allergan has agreed to acquire Bonti, a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Following completion of the acquisition, Allergan will obtain global rights to Bonti’s pipeline consisting of two botulinum neurotoxin serotype E (BoNT/E) programs currently in Phase 2 development: EB-001A (aesthetic) and EB-001T (therapeutic). The active ingredient in both programs, EB-001, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique clinical profile, characterized by a rapid onset of action within 24 hours and a two- to four-week duration of effect. Bonti recently announced topline results of the first clinical study of EB-001 in glabellar frown lines. The study confirmed both the safety and efficacy of the differentiated profile.
“The acquisition of Bonti is a strategic investment for the future of our medical aesthetics business and has the potential to enhance our best-in-class medical aesthetics pipeline,” said Brent Saunders, chairman and CEO of Allergan. “With the medical aesthetics market vastly expanding, a fast-acting neurotoxin with a two- to four-week duration will be an attractive option for consumers, particularly those who are considering a medical aesthetics treatment for the first time.”
Allergan will acquire Bonti for an upfront payment of $195M and additional potential commercial milestone payments.
